Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

Background: Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. Methods: One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. Results: In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53 v. 69 , P=0.012), despite higher mean age (51.8 v. 42.1 years, P
Original languageEnglish
Pages (from-to)240 - 248
Number of pages9
JournalSexual Health
Volume12
Issue number3
DOIs
Publication statusPublished - 2015

Cite this